Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bioventus (NASDAQ:BVS) is the #1 top healthcare stock out of 1066 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: B, Growth: A, Momentum: B, Sentiment: A, Safety: B, Financials: B, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 44, which is 18 points higher than the healthcare sector average of 26. It passed 14 out of 33 due diligence checks and has strong fundamentals. Bioventus has seen its stock return 72.73% over the past year, overperforming other healthcare stocks by 168 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 27.33% from Bioventus's current stock price of $11.78.

Bioventus stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Bioventus, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Immucell (NASDAQ:ICCC) is the #2 top healthcare stock out of 1066 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Immucell (NASDAQ:ICCC) is: Value: B, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: B.

Immucell (NASDAQ:ICCC) has a Due Diligence Score of 19, which is -7 points lower than the healthcare sector average of 26. Although this number is below the industry average, our proven quant model rates ICCC as a "A".It passed 6 out of 33 due diligence checks and has weak fundamentals. Immucell has seen its stock return 53.94% over the past year, overperforming other healthcare stocks by 149 percentage points.

Electromed (NYSEMKT:ELMD) is the #3 top healthcare stock out of 1066 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Electromed (NYSEMKT:ELMD) is: Value: C, Growth: C, Momentum: B, Sentiment: A, Safety: B, Financials: A, and AI: C.

Electromed (NYSEMKT:ELMD) has a Due Diligence Score of 44, which is 18 points higher than the healthcare sector average of 26. It passed 15 out of 33 due diligence checks and has strong fundamentals. Electromed has seen its stock return 130.17% over the past year, overperforming other healthcare stocks by 225 percentage points.

Electromed has an average 1 year price target of $38.00, a downside of -17.94% from Electromed's current stock price of $46.31.

Electromed stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Electromed, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 74 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 33.28%, which is 31 percentage points higher than the healthcare sector average of 2.65%.

Dominari Holdings's dividend payout ratio of -19.1% indicates that its high dividend yield might not be sustainable for the long-term.

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 16%, which is 13 percentage points higher than the healthcare sector average of 2.65%.

Siga Technologies's dividend payout ratio of 206.9% indicates that its high dividend yield might not be sustainable for the long-term.

Embecta (NASDAQ:EMBC) has an annual dividend yield of 14.02%, which is 11 percentage points higher than the healthcare sector average of 2.65%.

Embecta's dividend payout ratio of 31.2% indicates that its high dividend yield is sustainable for the long-term.

Healthcare stocks were down -0.32% in the last day, and up 2.16% over the last week. Adapthealth was the among the top losers in the healthcare sector, dropping -4.55% yesterday.

AdaptHealth shares are trading lower after Baird lowered its price target on the stock from $18 to $15.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 43, which is 30 points higher than the healthcare sector average of 13. It passed 3 out of 7 valuation due diligence checks.

Embecta's stock has dropped -67.3% in the past year. It has overperformed other stocks in the healthcare sector by 27 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 86, which is 73 points higher than the healthcare sector average of 13. It passed 6 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 514.31% in the past year. It has overperformed other stocks in the healthcare sector by 609 percentage points.

Inmode (NASDAQ:INMD) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Inmode has a valuation score of 57, which is 44 points higher than the healthcare sector average of 13. It passed 4 out of 7 valuation due diligence checks.

Inmode's stock has dropped -3.31% in the past year. It has overperformed other stocks in the healthcare sector by 91 percentage points.

61.98% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 27.99% over the next year.

5.22% of healthcare stocks have a Zen Rating of A (Strong Buy), 13.31% of healthcare stocks are rated B (Buy), 48.38% are rated C (Hold), 26% are rated D (Sell), and 7.09% are rated F (Strong Sell).